alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 31 studies in Risk factors in Innovation in Aging (page 1 of 2) · 28,580 in the whole library · How the 0–100 score works

Download bibliography of these 31 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 14,058 studies have no institution on record and are not counted here.

What “Risk factors” covers

Risk factors — Conditions, exposures and habits linked to a higher or lower chance of dementia, and how strong each link is.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Shelter-in-Place Policies, Proximity, and Changes in Caregiving for Older Adults During the COVID-19 Pandemic

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Innovation in Aging 2025-12-01

The study sample was NHATS respondents who needed assistance with activities of daily living (ADL) or instrumental activities of daily living (IADL), and who did not live with a spouse (N = 512). 3 key findings →

Participants: 512 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

ASSOCIATION BETWEEN VIOLENT CRIME INCIDENT PROXIMITY AND COGNITIVE FUNCTION IN OLDER AFRICAN AMERICANS

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Innovation in Aging 2022-11-01

Research on Area Deprivation Index (ADI) suggests that the built environment and neighborhood stressors (e.g., violent crime incidents) play a role in later-life cognitive function. 4 key findings →

Participants: 147 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

ACCESS TO NEIGHBORHOOD AMENITIES AND RISK OF INSTITUTIONALIZATION AMONG PERSONS WITH DEMENTIA

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Innovation in Aging 2023-12-01

This may be due to caregiving challenges associated with the behavioral symptoms PWD exhibit and their reduced capacities to perform daily tasks. 5 key findings →

Participants: 3,366 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Residential segregation exacerbates the effects of cardiovascular disease on cognition in Black older adults

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Innovation in Aging 2025-12-01

In highly segregated counties, Black older adults with elevated CVD demonstrated worse memory than those with lower CVD; in less segregated counties, memory levels did not differ by CVD. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Community Rates of Alzheimer’s Disease and Related Dementias and Supportive Services in CT, MA, & RI

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Innovation in Aging 2025-12-01

The consequences of Alzheimer’s Disease and Related Dementias (ADRD) are well documented, but beyond the individual, family, and health system costs are implications for communities that are not well-studied. 5 key findings →

Participants: 15 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

INDIVIDUAL AND COUNTY-LEVEL FACTORS OF SERVICE USE BY DEMENTIA FAMILY CAREGIVERS IN RURAL APPALACHIA

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Innovation in Aging 2023-12-01

These findings suggest that caregivers living in rural regions may depend more on informal support for meeting basic care needs of their relative living with dementia. 3 key findings →

Participants: 163 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neighborhood Disadvantage and Cognitive Function: The Moderating Role of Self-reported Loneliness

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Innovation in Aging 2025-12-01

Overall, our findings suggest that greater neighborhood disadvantage may influence select domains of memory, and that one’s self-reported loneliness may influence how this relationship manifests. 4 key findings →

Participants: 136 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Inflammation and Cognition: The Moderating Role of Neighborhood Disadvantage

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Innovation in Aging 2025-12-01

Specifically, higher inflammation was associated with worse processing speed (B = -0.01; p < .05) and working memory (B = 8323.66; p < .1) only among those from more disadvantaged neighborhoods. 3 key findings →

Participants: 51 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

ACCESS TO HIGH-QUALITY HOME HEALTH CARE FOR PERSONS WITH DEMENTIA

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Innovation in Aging 2024-12-01

Using multiple Medicare Public Use Files (PUF), including star ratings for home health quality of patient care (QoPC), home health care CAHPS survey (HHCAHPS), county-level ADRD prevalence, and Medicare FFS enrollment, we found that the median county-level number of home health agencies was 15 (IQR 8-29), star rating was 3.4 (IQR 3.1-3.7) for QoPC and 3.8 (IQR 3.5-4.0) for HHCAHPS. 2 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

RICHMOND HEALTH AND WELLNESS PROGRAM: COMMUNITY ADVISORY COUNCIL OUTCOMES

✓ Peer-reviewed alzhub usefulness score 30 out of 100. Innovation in Aging 2018-11-01

The Richmond Health and Wellness Program (RHWP) provides interprofessional care coordination and wellness services within Richmond’s low income senior housing communities for approximately 1,000 subsidized housing units. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed